In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e13603-e13603
Abstract:
e13603 Background: MLN9708 is a potent, reversible, orally bioavailable, and specific 20S proteasome inhibitor. This study (NCT00830869) assessed the safety, MTD, PK, PD, and antitumor activity of intravenous (IV) MLN9708 in pts with solid tumors. Methods: Pts aged ≥18 yrs (ECOG PS 0–2) received increasing doses of IV MLN9708 (starting at 0.125 mg/m 2 ) on days 1, 4, 8, and 11 of 21-day cycles, for up to 12 cycles. MTD expansion cohorts included head and neck (H & N) cancer, non-small cell lung cancer, soft tissue sarcoma, prostate cancer, and a tumor PD expansion cohort. Plasma PK and blood PD data were analyzed by a non-compartmental method using WinNonlin software v5.3. The candidate PD biomarker ATF-3 was assessed using IHC. Results: 113 pts were enrolled; 23 in dose escalation and 96 in MTD expansion (includes 6 from dose escalation) cohorts. Median age of these heavily pretreated pts was 58 yrs (range 29–80). MTD was established as 1.76 mg/m 2 . Pts have received a median of 2 cycles (range 1–12) to date (data cut-off Dec 1, 2011); 22 received ≥4 cycles. 88% had ≥1 drug-related AE; most common drug-related AEs included fatigue (40%), thrombocytopenia (39%), rash (high level term) (33%), and nausea (32%). 52% of pts experienced grade ≥3 drug-related AEs, including thrombocytopenia (20%) and rash (9%). Drug-related peripheral neuropathy (PN) was seen in 13% of pts; 2 pts had grade 3 PN. 25% had drug-related SAEs, 15% discontinued due to AEs; 7 pts died, all unrelated to treatment. Of 75 response-evaluable pts, 26 achieved SD. A partial response (PR) was observed in a pt in the H & N cohort; response was achieved after 4 cycles and maintained through 8 cycles. Change in ATF-3 levels in tumor tissue post treatment was seen in 6 patients with tumor biopsy samples, indicating proteasome inhibition. PK data showed three-exponential plasma disposition, half-life of ~4–8 days, and dose linearity from 0.5–2.34 mg/m 2 . At MTD, maximal 20S proteasome inhibition in blood was approximately 60% at 0.08 hours. Whole blood PD effect was immediate and dose dependent. Conclusions: These data suggest that twice-weekly IV MLN9708 has a generally manageable safety profile and potential clinical utility; updated results will be presented.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e13603
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
Bookmarklink